CareerPlanAI job matching →
Menarini logo

Menarini Jobs

About Menarini

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp

6 Open Roles

6 open roles · apply directly
Don't apply alone — put your search on autopilot.
CareerPlan is passive job search: upload your CV once, we apply to roles like these for you and surface only real interviews.
Start passive job search — free →